Company intelligence / Profile preview

LeonaBio

Bothell, Washington, United Statesleonabio.com ↗

Ownership: Public · LONA
Employees: ~75
Development stage: Phase 3

Overview

LeonaBio is currently advancing its lead asset, lasofoxifene, in the pivotal Phase 3 ELAINE-3 clinical trial for metastatic breast cancer, with data expected in mid-2027. The company's second lead candidate, ATH-1105, recently completed a Phase 1 first-in-human trial in 80 healthy volunteers, demonstrating safety and tolerability; a Phase 2 trial in patients with ALS is planned for initiation in early 2026.

Therapeutic areas: OncologyNeurology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

10 assets

lasofoxifene

9 more assets in the full pipeline.

Request access →

Partnerships

Sermonix Pharmaceuticals

Financials

Market cap: $32.3M
Total revenue: $0
Enterprise value: $-18.2M

Beyond the preview

Go deeper on LeonaBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LeonaBio.

Explore the full profile